Balsm Alofoq Medical Co. posted net profits of SAR 1.3 million in the first half of 2025, down 6% from SAR 1.4 million in H1 2024.
Item | H1 2024 | H1 2025 | Change |
---|---|---|---|
Revenues | 9.55 | 9.76 | 2.2 % |
Net Income | 1.43 | 1.34 | (6.4 %) |
Average Shares | 1.00 | 1.25 | 25.0 % |
Earnings Per Share before unusual items (Riyal) | 1.43 | 1.07 | (25.1 %) |
EPS (Riyal) | 1.43 | 1.07 | (25.1 %) |
Item | H2 2024 | H1 2025 | Change |
---|---|---|---|
Revenues | 10.31 | 9.76 | (5.3 %) |
Net Income | 3.35 | 1.34 | (59.8 %) |
Average Shares | 1.25 | 1.25 | - |
Earnings Per Share before unusual items (Riyal) | 2.68 | 1.07 | (59.8 %) |
EPS (Riyal) | 2.68 | 1.07 | (59.8 %) |
The six-month profit was weighed by new investments as the company expanded its business in the fields of medical services and the sale of medical devices and equipment.
During the same period, the company also expanded into the maintenance of medical equipment in the government sector.
On the other hand, revenues grew by 2.2% year-on-year (YoY) during the first six months of this year. This was mainly due to the company’s growth and expansion strategy and increased market share.
On a half-on-half basis, Balsm Alofoq’s six-month bottom line shrank by 59.8% from SAR 3.35 million in H2 2024.
Total shareholders’ equity, no minority interest, rose to SAR 30.26 million as of June 30, 2025, from SAR 15.82 million a year earlier.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: